FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment

Elske Quak · Iringo Kovacs · Wim J. G. Oyen · Winette T. A. van der Graaf

Introduction

The role of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to detect viable tumour in the follow-up of patients with non-seminoma testis and residual masses is still not conclusively shown, and studies to further define this role show variable results [1–5]. However, the value of FDG-PET/CT in the follow-up of individual patients with mature teratoma and secondary gliosarcoma can be essential in guiding the sequence and extent of further treatment, as illustrated by the following case.

Case report

A 41-year-old man first visited the urologist in a general hospital because of gynaecomasty and a mass in the right groin 6 years ago. He had a history of a left-sided orchidectomy as a baby, and a surgical correction of a right-sided inguinal hernia at the age of 31. Because of an abnormal ultrasound of the right testicle and increased tumour markers in the blood, a radical inguinal right-sided funiculo-orchidectomy was performed, and a testicular prosthesis was placed. The resection specimen showed a non-seminomatous testicular cancer, which consisted purely of embryonic cell carcinoma without components of teratoma. The contrast-enhanced CT of the thorax and abdomen performed the day after the orchidectomy showed extensive abdominal lymph node metastases, multiple liver metastases, metastases in the left adrenal gland and metastases in the right inguinal region.

Because of this poor-risk non-seminomatous testicular cancer, the patient was referred to the Oncology Department of our University Medical Centre. Initial serum markers were: lactate dehydrogenase (LDH) 1,534 U/l (normal, <250 U/l), beta-human chorionic gonadotropin (beta-HCG) 17.5 ng/ml.
(normal, <1.0 ng/ml) and alpha-fetoprotein (AFP) 527 μg/l (normal, <3.0 μg/l). Chemotherapy with bleomycin, etoposide and cisplatin (BEP) was started immediately. The patient tolerated the four cycles of chemotherapy relatively well. Within 2 months after the start of chemotherapy, the serum tumour markers normalised. However, contrast-enhanced CT after completion of the chemotherapy showed a mixed response: the lesion in the left adrenal gland and the abdominal lymph node metastases had declined, but the lesions in the liver and the right inguinal region showed an increase in size (Fig. 1). Because of the normal serum tumour markers and the radiological aspects of these growing lesions, growing teratoma was suspected. Biopsy of one of the liver lesions showed no malignancy. Whilst planning extensive surgery for the suspected teratoma lesions in the liver, the patient unfortunately presented with a biochemical relapse (AFP, 47.1 μg/l) of his non-seminomatous testicular cancer and a deterioration of his renal function due to obstruction of the right ureter by a tumour mass. The surgery was postponed and a double-J catheter was inserted in the obstructed right ureter, after which the renal function normalised. To evaluate the extent of the disease, FDG-PET/CT was performed, which showed multiple small liver lesions with a high metabolic activity and two highly metabolic active regions in the right inguinal mass, all suspected to be metabolically active malignant tumour. FDG-PET/CT also showed two large liver lesions without increased FDG uptake, probably teratomas. Because of the recurrent non-seminomatous testicular cancer, the patient was treated with four cycles of second line chemotherapy consisting of paclitaxel, ifosfamide and cisplatin (TIP). The serum tumour markers normalised and follow-up FDG-PET/CT performed after two cycles of chemotherapy showed a complete metabolic response in all lesions.

However, a further FDG-PET/CT performed after completion of the four cycles of chemotherapy showed new, highly metabolically active lymph nodes in the retro peritoneum again suggestive for viable tumour, whilst the serum tumour markers remained normal. The patient underwent a retroperitoneal lymph node dissection, including resection of these FDG avid regions, which showed mature teratoma with secondary malignant components of papillary carcinoma and astrocytoma grade II (Fig. 2).

A few months later, a follow-up FDG-PET/CT showed increasing metabolic activity in the right inguinal mass and in a liver lesion. First, a right sidedinguinal lymph node dissection was done, which showed teratoma with a neuroglial component of uncertain malignant potency (Fig. 3). Subsequently, a partial resection of the liver was performed, which showed teratoma with the same known neuroglial component and a lesion with secondary malignant degeneration, possibly gliosarcoma or pleomorphic malignant fibrous histiocytoma (Fig. 4).

After surgery, the patient was in excellent health and remained free of disease for more than a year. However, during follow-up, FDG-PET/CT showed a hypermetabolic tumour in the musculature of the right upper leg. To rule out metastases, this lesion was excised, and it appeared to be a nodular fasciitis on pathological examination. The first follow-up FDG-PET/CT, 2 months after resection of the nodular fasciitis, showed increasing metabolic activity in one of the teratomas in the liver and in the postsurgical region in the liver. Again, the affected segments were excised, which showed mature teratoma with secondary malignant degeneration with neuroglial and probably mesenchymal components.

![Fig. 1](image1) Contrast-enhanced axial CT images before (a, c) and after (b, d) the first line of chemotherapy showed a regression of the left adrenal metastases (a, b) and a clear progression of the liver metastases (c, d).

![Fig. 2](image2) The FDG-PET (a) and FDG-PET/CT (b) images showed a hypermetabolic region (dotted arrow) in an otherwise relatively photopenic mass (straight arrows) in the retroperitoneum. Histology after surgical excision showed mature teratoma with an astrocytoma grade II component (not shown) and a papillary carcinoma component (c). Note the cystic spaces consistent with mature teratoma and the papillary carcinoma in the right lower corner of the image (c), with glandular and papillary structures, atypical cells and mitotic figures (d).
tumour from necrosis, fibrosis or teratoma in non-surgical interventions. This patient has clearly benefitted from a multidisciplinary approach, leading to multiple successful FDG-PET/CT-guided interventions in the retroperitoneum and extra-retroperitoneal. The risk that these masses contain viable germ cell tumour on pathological examination is reported to be about 10 % and is associated with poor clinical outcome [6]. We feel that the outcome of this patient has clearly benefited from a multidisciplinary approach, leading to multiple successful FDG-PET/CT-guided surgical interventions.

The ability of FDG-PET to differentiate viable germ cell tumour from necrosis, fibrosis or teratoma in non-seminomatous testicular cancer patients with residual masses after chemotherapy was shown by several studies [7, 8]. The FDG uptake in viable tumour was significantly higher than the generally low FDG uptake in necrosis, fibrosis or teratoma. However, FDG-PET could not differentiate between teratoma, low-grade malignancy and fibrosis or necrosis. The clinical relevance of these findings is debatable, because in general, the consensus is that teratomas, hypermetabolic or not, should be removed because of the potential of malignant dedifferentiation and because growth can cause mechanical problems [9–11]. In this particular case, however, resection of all the teratomas in the liver would only be possible by performing a liver transplantation. FDG-PET/CT allowed for correct localisation of the malignant tissue and served as a guide for the surgical interventions.

The overall performance of FDG-PET compared with contrast-enhanced CT and serum tumour markers in patients with residual masses after chemotherapy in non-seminomatous testicular cancer was prospectively studied by Oechsle et al. [3], with histological confirmation in all patients. The accuracy of FDG-PET in the detection of viable tumour was not significantly better than that of CT or serum tumour markers (56, 55 and 56 % respectively). Sensitivities and specificities of FDG-PET for the detection of viable tumour reported in the literature vary between 59 and 70 % and 48 and 92 %, respectively [2, 3]. Hain et al. [12] reported a management change due to FDG-PET in 57 % of patients with testicular cancer. However, it must be noted that most of the FDG-PET studies in metastasised non-seminomatous testicular cancer, including these studies, were performed on earlier generation (stand-alone) PET scanners. Nowadays, hybrid PET/CT scanners are used, allowing for anatomical correlation in PET interpretation, and new techniques in image reconstruction, such as time-of-flight, improve spatial resolution in PET imaging. In our experience, these techniques improve the overall performance of FDG-PET/CT, and we expect the results of FDG-PET/CT in metastasised non-seminomatous testicular cancer to be superior to the aforementioned results, as is suggested in a recent study by Sterbis et al. [13] using fusion imaging in testicular cancer.

This patient also demonstrated a non-malignant hypermetabolic muscular lesion in the right upper leg, which proved to be a nodular fasciitis. Non-malignant, positive FDG-PET/CT findings due to inflammatory conditions, for example, are a well-known caveat in the differential diagnosis of FDG-accumulating lesions, as these can mimic or coexist with malignancy [14].

In conclusion, in selected cases, surveillance of patients with non-seminomatous testicular cancer with FDG-PET/CT can guide major treatment decisions when considering surgery for metastatic disease, mature teratoma or even secondary degenerated mature teratoma.
Acknowledgments  The authors would like to thank Dr Nicolas Aide, François Baclesse Cancer Center, for his help in creating the illustrations.

Conflict of Interest  Elske Quak, Iringo Kovacs, Wim J.G. Oyen and Winette T.A. van der Graaf have nothing to declare.

Informed Consent  Informed consent was obtained from the patient for whom identifying information is included in this article.

Open Access  This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Huddart RA, O’Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22—the NCRI testis tumour clinical study group. J Clin Oncol. 2007;25:3090–5.

2. Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, et al. Prospective comparison of [18 F] fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer. 2002;94:2353–62.

3. Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, et al. [18F] Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26:5930–5.

4. Karapetis CS, Strickland AH, Yip D, Steer C, Harper PG. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. J Int Med Res. 2003;33:427–35.

5. Spermon JR, De Geus-Oei LF, Kiemeneij LA, Witjes JA, Oyen WJ. The role of (18) fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002;89:549–56.

6. Masterson TA, Shayegean B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, et al. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology. 2012;79:156–9.

7. Stephens AW, Gornik R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 1996;14:1637–41.

8. Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, et al. The role of [(18) F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors—prospects for management. World J Urol. 2004;22:132–9.

9. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European germ cell cancer consensus group (EGCCCG): part II. Eur Urol. 2008;53:497–513.

10. Carver BS, Sheinfeld J. Management of post-chemotherapy extraretroperitoneal residual masses. World J Urol. 2009;27:489–92.

11. Daneshmand S, Djladat H, Nichols C. Management of residual mass in nonseminomatous germ cell tumors following chemotherapy. Ther Adv Urol. 2011;3:163–71.

12. Hain SF, O’Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer. 2000;83:863–9.

13. Sterbis JR, Rice KR, Javitt MC, Schenkman NS, Brassell SA. Fusion imaging: a novel staging modality in testis cancer. J Cancer Educ. 2010;1:223–9.

14. Aide N, Allouache D, Ollivier Y, de Raucourt S, Swissers O, Bardet S. Early 2′-deoxy-2′-[18F]fluoro-D-glucose PET metabolic response after corticosteroid therapy to differentiate cancer from sarcoidosis and sarcoid-like lesions. Mol Imaging Biol. 2009;11:224–8.